期刊
NEUROSCIENCE LETTERS
卷 595, 期 -, 页码 116-121出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2015.04.014
关键词
Alzheimer disease; Biomarker; Gelsolin; Matrix metalloproteinase 3; Plasma
资金
- China-Canada Joint Initiative on Alzheimer's Disease and Related Disorders [81261120571]
- Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals [ZY201301]
- Seed Grant of International Alliance of Translational Neuroscience [PXM2014_014226_000006]
- National Science and Technology Major Projects for Major New Drug Innovation and Development of the Twelfth 5-year Plan Period [2011ZX09307-001-03]
- National Key Technology R&D Program in the Eleventh Five-year Plan Period [2006BAI02B01]
- key project of the National Natural Science Foundation of China [30830045]
- Scientific promoting project of Beijing Institute for Brain Disorders [BIBDPXM2014_014226_000016]
Gelsolin (GSN) levels and matrix metalloproteinase 3 (MMP3) activity have been found to be altered in the plasma in patients with Alzheimer disease (AD). The aim of this study was to determine whether a combination of these proteins with clinical data is specific and sensitive enough for AD diagnosis. In 113 non-demented controls and 113 patients with probable AD, the plasma GSN levels were determined using the enzyme-linked immunosorbent assay (ELISA), and the plasma MMP3 activity was determined using casein zymography. Logistic regression and receiver operating characteristic (ROC) curve analysis were used to determine the diagnostic accuracy of these proteins combined with clinical data. Compared with the controls, the AD patients had significantly lower GSN levels and significantly higher MMP3 activity. Moreover, both the GSN level and MMP3 activity were significantly correlated with the MMSE scores. In AD patients, the GSN level was negatively correlated with MMP3 activity. ROC curve analysis showed that the specificity and sensitivity were 77% and 75.2%, respectively, for the combination of the following candidate biomarkers: GSN level/the total amount of A beta(42) and A beta(40), plasma MMP3 activity and clinical data. With its relatively high sensitivity and specificity, this combined biomarker panel may have potential for the screening of AD patients. 2015 (C) Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据